XML 22 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Total National Health Investors Stockholders’ Equity
Common Stock
Capital in Excess of Par Value
Retained Earnings
Cumulative Dividends
Accumulated Other Comprehensive Income
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2020     45,185,992          
Beginning balance, amount at Dec. 31, 2020 $ 1,522,945 $ 1,512,234 $ 452 $ 1,540,946 $ 2,304,909 $ (2,326,924) $ (7,149) $ 10,711
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Distributions declared to noncontrolling interests (974)             (974)
Total other comprehensive income 119,116 118,953     111,804   7,149 163
Equity component in redemption of convertible debt $ (6,076) (6,076)   (6,076)        
Issuance of common stock, net (in shares) 661,951   661,951          
Net income, excluding, excluding a loss attributable to redeemable noncontrolling interests $ 111,804              
Issuance of common stock, net & Equity issuance cost 47,904 47,904 $ 7 47,897        
Shares issued on stock options exercised (in shares)     2,656          
Share-based compensation 8,415 8,415   8,415        
Dividends declared (174,347) (174,347)       (174,347)    
Ending balance (in shares) at Dec. 31, 2021     45,850,599          
Ending balance, amount at Dec. 31, 2021 1,516,983 1,507,083 $ 459 1,591,182 2,416,713 (2,501,271) 0 9,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Distributions declared to noncontrolling interests (1,015)             (1,015)
Net income, excluding loss attributable to redeemable noncontrolling interest 66,344 66,403     66,403     (59)
Total other comprehensive income 65,501              
Reclassification of redeemable noncontrolling interest $ 1,030             1,030
Issuance of common stock, net (in shares) 0              
Net income, excluding, excluding a loss attributable to redeemable noncontrolling interests $ 66,403              
Issuance of common stock, net & Equity issuance cost (80) (80)   (80)        
Taxes paid/remitted on employee stock options exercised & awards $ (288) (288)   (288)        
Shares issued on stock options exercised (in shares)     6,497          
Repurchases of common stock (in shares) (2,468,354)   (2,468,354)          
Repurchases of common stock $ (151,951) (151,951) $ (25)   (151,926)      
Share-based compensation 8,613 8,613   8,613        
Dividends declared $ (159,555) (159,555)       (159,555)    
Ending balance (in shares) at Dec. 31, 2022 43,388,742   43,388,742          
Ending balance, amount at Dec. 31, 2022 $ 1,280,081 1,270,225 $ 434 1,599,427 2,331,190 (2,660,826) 0 9,856
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Noncontrolling interests capital contributions, excluding $922 attributable to redeemable noncontrolling interest 2,051             2,051
Distributions declared to noncontrolling interests (1,286)             (1,286)
Net income, excluding loss attributable to redeemable noncontrolling interest 135,472 135,654     135,654     (182)
Total other comprehensive income $ 134,381              
Issuance of common stock, net (in shares) 0              
Net income, excluding, excluding a loss attributable to redeemable noncontrolling interests $ 135,654              
Issuance of common stock, net & Equity issuance cost $ (275) (275)   (275)        
Grants of restricted stock (in shares)     21,000          
Shares issued on stock options exercised (in shares) 5,166   99          
Shares issued on stock options exercised $ 0 0 $ 0 0        
Share-based compensation 4,605 4,605   4,605        
Dividends declared $ (156,257) (156,257)     0 (156,257)    
Ending balance (in shares) at Dec. 31, 2023 43,409,841   43,409,841          
Ending balance, amount at Dec. 31, 2023 $ 1,264,391 $ 1,253,952 $ 434 $ 1,603,757 $ 2,466,844 $ (2,817,083) $ 0 $ 10,439